Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Authors
Butts, CSocinski, M
Mitchell, Pa
Thatcher, Nick
Havel, L
Krzakowski, M
Nawrocki, S
Ciuleanu, T
Bosquée, L
Trigo, J
Spira, A
Tremblay, L
Nyman, J
Ramlau, R
Wickart-Johansson, G
Ellis, P
Gladkov, O
Pereira, J
Eberhardt, W
Helwig, C
Schröder, A
Shepherd, F
Affiliation
Cross Cancer Institute, Edmonton, AB, CanadaIssue Date
2014-01
Metadata
Show full item recordAbstract
Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation.Citation
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. 2014, 15 (1):59-68 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(13)70510-2PubMed ID
24331154Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(13)70510-2